Opexa autoimmune news

Opexa reduced headcount by 10 (28%) to 26 to conserve cash and focus resources on completing the Phase IIb Abili-T trial of Tcelna imilecleucel-T to treat secondary progressive multiple sclerosis (SPMS). The cuts include CFO Karthik Radhakrishnan. Opexa expects top-line data from Abili-T in 4Q16. Tcelna comprises patient-specific myelin reactive T cells (MRTCs) primed and expanded ex vivo with myelin-associated peptides. Opexa declined to disclose anticipated savings to operating costs but said it expects the restructuring to extend its cash runway into 1Q17. At Dec. 31, 2015, the company had $12.6 million in cash and a 12-month operating loss of $12.1 million. ...